AK1

AK1 is a cytosolic phosphotransferase that sustains intracellular energy communication and nucleotide homeostasis, functioning as a critical node in the high-energy phosphoryl relay between ATP-producing and ATP-consuming sites (PMID:11006295, PMID:2261892). In the heart, AK1-catalyzed beta-phosphoryl transfer maintains myocardial energetic homeostasis under metabolic stress: its loss lowers intracellular ATP, raises the Pi/ATP ratio, suppresses adenosine generation, and accelerates contractile failure at the onset of ischemia, with residual phosphotransfer compensated by other AK isoforms, creatine kinase, and glycolytic flux (PMID:11006295, PMID:12124227). AK1 phosphotransfer also synchronizes Pi turnover at ATP-consuming sites with gamma-ATP exchange at synthesis sites and couples cardiac contractility to coronary flow, with a sarcolemma-associated splice variant AK1beta facilitating adenosine production that rescues post-ischemic coronary reflow (PMID:17704060). In skeletal muscle, AK1 contributes to phosphoryl delivery to the actomyosin ATPase, and its combined disruption with cytosolic creatine kinase severely curtails total ATP turnover and contractile performance (PMID:12730234). The AK1 gene generates two isoforms via alternative promoters and polyadenylation—cytosolic AK1 and N-terminally distinct membrane-bound AK1beta, which localizes to the plasma membrane and mediates AMP-induced activation of ATP-sensitive potassium channels (PMID:14977170). Human loss-of-function mutations abolishing erythrocyte AK activity cause congenital chronic hemolytic anemia, identifying Tyr164 and Arg107 as residues essential for enzymatic function (PMID:9432020, PMID:10233365).

1. 1988 High

   Establishing whether the adenylate kinase gene is essential and whether redundant isozymes exist was answered first in yeast, where disruption impaired proliferation but not viability and left residual AK activity.

   Evidence ADK1 gene disruption with immunological assay and 31P NMR in S. cerevisiae

   PMID:2848829

   Open questions at the time

   • Does not address mammalian isoform organization
   • Identity of the compensating isozymes not defined
2. 1990 Medium

   Defining where AK1 acts and distinguishing it from mitochondrial AK2 established AK1 as the cytosolic isoenzyme across multiple tissues.

   Evidence Isoelectric focusing, monoclonal antibody immunostaining, and partial purification from bovine tissues

   PMID:2261892

   Open questions at the time

   • Subcellular distribution inferred biochemically, not by live imaging
   • Functional consequence of cytosolic localization not tested
3. 1997 Medium

   Linking AK1 to human disease, a Tyr164Cys substitution abolishing erythrocyte AK activity established the residue as functionally critical and tied AK1 loss to hemolytic anemia.

   Evidence PCR-SSCP, Sanger sequencing, and spectrophotometric AK assay in patient red cells

   PMID:9432020

   Open questions at the time

   • Single family
   • Mechanism linking enzyme loss to hemolysis not resolved
4. 1999 Medium

   A nonsense Arg107Stop allele producing a truncated inactive protein confirmed the genotype-phenotype link and extended it to psychomotor impairment.

   Evidence cDNA sequencing and erythrocyte AK activity assay in patients

   PMID:10233365

   Open questions at the time

   • Single family
   • Basis of neurological involvement not established
5. 2000 High

   Determining AK1's quantitative role in cardiac energetics, a knockout showing near-total loss of AK phosphotransfer with collapse of ATP buffering and adenosine signaling under hypoxia established AK1 as essential for myocardial energetic homeostasis under stress.

   Evidence [18O] phosphoryl analysis, 31P NMR, and mass spectrometry in AK1 knockout mouse hearts

   PMID:11006295

   Open questions at the time

   • Compensating pathways not yet quantified
   • Does not address membrane-bound isoform
6. 2002 High

   Resolving how hearts survive AK1 loss, ischemia-reperfusion studies showed compensatory creatine kinase, glycolytic, and AK-isoform flux restores postischemic recovery despite acute contractile vulnerability.

   Evidence 31P NMR, 18O labeling, and metabolite assays in AK1 knockout hearts under ischemia-reperfusion

   PMID:12124227

   Open questions at the time

   • Identity and regulation of upregulated AK isoforms not detailed
7. 2003 High

   Testing AK1's contribution to muscle ATPase fueling, double knockout with M-CK demonstrated that AK1 phosphotransfer supports phosphoryl delivery to the actomyosin ATPase and total ATP turnover under load.

   Evidence 18O labeling, in vitro actomyosin complex assay, and metabolite measurements in M-CK/AK1 double-knockout skeletal muscle

   PMID:12730234

   Open questions at the time

   • Relative contribution of AK1 alone versus M-CK not separated
   • Mechanism of phosphoryl channeling to ATPase not structurally defined
8. 2004 High

   Characterizing the gene's two products, alternative promoter/polyadenylation usage was shown to yield cytosolic AK1 and membrane-bound AK1beta, the latter activating KATP channels, linking AK1 phosphotransfer to membrane excitability.

   Evidence Northern analysis, transfection localization, in vitro phosphorylation, and patch-clamp of recombinant KATP channels

   PMID:14977170

   Open questions at the time

   • Endogenous tissue distribution of AK1beta not mapped
   • Direct channel interaction versus local nucleotide effect not distinguished
9. 2005 High

   Directly measuring the metabolic cost of AK1 loss in muscle revealed large free ADP accumulation during fatiguing contractions, yet fatigue profiles were unchanged, indicating redundancy in energetic buffering.

   Evidence 31P NMR of in situ contracting gastrocnemius in AK1 knockout mice

   PMID:15689408

   Open questions at the time

   • Compensating buffering systems not identified in this assay
10. 2007 High

    Connecting AK1 to vascular function, knockout studies showed AK1 deletion uncouples contractility from coronary flow and that AK1beta-facilitated adenosine production, restorable pharmacologically, drives post-ischemic coronary reflow.

    Evidence 18O-assisted 31P NMR, coronary flow measurement, and adenosine rescue in AK1 knockout hearts

    PMID:17704060

    Open questions at the time

    • Step linking AK1beta to adenosine-producing enzymes not defined
    • AK1beta-specific genetic ablation not performed
11. 2023 Medium

    Identifying a context-specific binding partner, ODF4 was shown to co-IP with AK1 and be required for AK1 retention in sperm flagella, linking AK1 localization to flagellar morphology and male fertility.

    Evidence Reciprocal Co-IP, Odf4 knockout/rescue mouse model, immunolocalization, and fertility assays

    PMID:36804949

    Open questions at the time

    • Single lab
    • Whether ODF4 binds AK1 directly versus within a complex not resolved
    • Functional role of flagellar AK1 not directly tested
12. 2024 Medium

    Defining pharmacological modulation, dinucleoside polyphosphates including Ap5A were shown to potently inhibit human AK1 in vitro, providing chemical tools and structural binding models.

    Evidence In vitro enzymatic inhibition with purified hAK1, molecular docking, and QSAR analysis

    PMID:38744169

    Open questions at the time

    • No mutagenesis validation of docked binding mode
    • Cellular efficacy not tested

• How AK1beta is physically coupled to KATP channels and adenosine-generating enzymes at the sarcolemma, and whether the cytosolic and membrane isoforms have separable in vivo roles, remains unresolved.
• No isoform-specific knockout reported
• No structure of AK1beta-channel assembly
• Direct adenosine-generation enzyme partner not identified